Drug development of intranasally delivered peptides

Therapeutic Delivery

Volumn 3, Issue 4, 2012, Pages 557-568

  Campbell, Catherine ^a   Morimoto, Bruce H ^a   Nenciu, Daniela ^a   Fox, Anthony W ^b  

^a Allon Therapeutics Inc   (Canada)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALGINIC ACID; BESTATIN; BETA CYCLODEXTRIN DERIVATIVE; BUSERELIN; CALCITONIN; CHITOSAN; DAVUNETIDE; DEXTRAN; ERYTHROPOIETIN; FENTANYL; GENTAMICIN; GLYCOCHOLIC ACID; INSULIN; LIPOSOME; MICROSPHERE; MIDAZOLAM; NERVE GROWTH FACTOR; OREXIN; PEPTIDE DERIVATIVE; POLIDOCANOL; POLYLACTIDE; PROGESTERONE; PROPRANOLOL; PROTIRELIN; PUROMYCIN; REMOXIPRIDE; SULFASOMIDINE; UNINDEXED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

AIRFLOW; AMINO TERMINAL SEQUENCE; CARBOXY TERMINAL SEQUENCE; CENTRAL NERVOUS SYSTEM; DRUG ABSORPTION; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DELIVERY SYSTEM; DRUG EXPOSURE; DRUG FORMULATION; DRUG INDICATION; DRUG SAFETY; DRUG SOLUBILITY; ENCAPSULATION; HUMAN; HYDROPHOBICITY; INTRANASAL DRUG ADMINISTRATION; IONIZATION; ISOELECTRIC POINT; LIPOPHILICITY; MAXIMUM PLASMA CONCENTRATION; NERVE FIBER TRANSPORT; NONHUMAN; NOSE CAVITY; OLFACTORY EPITHELIUM; OSMOLARITY; PATENT; PHYSICAL CHEMISTRY; PLASMID; PRIORITY JOURNAL; PROTEIN TRANSPORT; REVIEW; TOXICOKINETICS; VISCOSITY;

EID: 84859250596     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.12.12     Document Type: Review

References (80)

1. Illum L, Hinchcliffe M, Davis SS. The effect of blood sampling site and physicochemical characteristics of drugs on bioavailability after nasal administration in the sheep model. Pharm. Res. 20(9), 1474-1484 (2003). (Pubitemid 37164057)
2. Hussain AA. Intranasal drug delivery. Adv. Drug Deliv. Rev. 29(1-2), 39-49 (1998). (Pubitemid 28044085)
3. Thorne RG, Frey WH 2nd. Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin. Pharmacokinet. 40(12), 907-946 (2001). (Pubitemid 34066688)
4. O'Hagan DT, Illum L. Absorption of peptides and proteins from the respiratory tract and the potential for development of locally administered vaccine. Crit. Rev. Ther. Drug Carrier Syst. 7(1), 35-97 (1990). (Pubitemid 20355577)
5. Illum L. Nasal drug delivery-possibilities, problems and solutions. J. Control. Release 87(1-3), 187-198 (2003). (Pubitemid 36255456)
6. Harkema JR, Carey SA, Wagner JG. The nose revisited: a brief review of the comparative structure, function, and toxicologic pathology of the nasal epithelium. Toxicol. Pathol. 34(3), 252-269 (2006).
7. Hoekman JD, Ho RJ. Enhanced analgesic responses after preferential delivery of morphine and fentanyl to the olfactory epithelium in rats. Anesth. Analg. 113(3), 641-651 (2011).
8. Westin UE, Bostrom E, Grasjo J, Hammarlund-Udenaes M, Bjork E. Direct nose-to-brain transfer of morphine after nasal administration to rats. Pharm. Res. 23(3), 565-572 (2006).
9. Wu H, Hu K, Jiang X. From nose to brain: understanding transport capacity and transport rate of drugs. Expert Opin. Drug Deliv. 5(10), 1159-1168 (2008).
10. Born J, Lange T, Kern W, Mcgregor GP, Bickel U, Fehm HL. Sniffing neuropeptides: a transnasal approach to the human brain. Nat. Neurosci. 5(6), 514-516 (2002). (Pubitemid 34568991)
11. Dhuria SV, Hanson LR, Frey WH. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J. Pharm. Sci. 99(4), 1654-1673 (2010).
12. Faber WM. The nasal mucosa and the subarachnoid space. J. Anat. 62(1), 121-148 (1937).
13. Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur. J. Pharm. Sci. 11(1), 1-18 (2000). (Pubitemid 30410839)
14. Merkus P, Guchelaar HJ, Bosch DA, Merkus FW. Direct access of drugs to the human brain after intranasal drug administration? Neurology 60(10), 1669-1671 (2003). (Pubitemid 36618097)
15. Jerusalmi A, Morris-Downes M, Sheahan BJ, Atkins GJ. Effect of intranasal administration of Semliki Forest virus recombinant particles expressing reporter and cytokine genes on the progression of experimental autoimmune encephalomyelitis. Mol. Ther. 8(6), 886-894 (2003). (Pubitemid 38072301)
16. Henriksson J, Tjalve H. Manganese taken up into the CNS via the olfactory pathway in rats affects astrocytes. Toxicol. Sci. 55(2), 392-398 (2000). (Pubitemid 30353248)
17. Danielyan L, Schafer R, von Ameln-Mayerhofer A et al. Therapeutic efficacy of intranasally delivered mesenchymal stem cells in a rat model of Parkinson disease. Rejuvenation Res. 14(1), 3-16 (2011).
18. Hanson LR, Frey WH 2nd. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci. 9(Suppl. 3), S5 (2008).
19. Thorne RG, Pronk GJ, Padmanabhan V, Frey WH. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience. 127(2), 481-496 (2004). (Pubitemid 38950662)
20. Giroux M, Hwang P, Prasad A. Controlled particle dispersion: applying vortical flow to optimize nasal drug deposition. Drug Deliv. Technol. 5(3), 6 (2005).
21. Djupesland PG, Skretting A, Winderen M, Holand T. Breath actuated device improves delivery to target sites beyond the nasal valve. Laryngoscope 116(3), 466-472 (2006). (Pubitemid 44318113)
22. Maggio ET. Intravail: highly effective intranasal delivery of peptide and protein drugs. Expert Opin. Drug Deliv. 3(4), 529-539 (2006).
23. Stevens J, Ploeger BA, Van Der Graaf PH, Danhof M, De Lange EC. Systemic and direct nose-to-brain transport pharmacokinetic model for remoxipride after intravenous and intranasal administration. Drug Metab. Dispos. 39(12), 2275-2282 (2011).
24. Merkus FW, Van Den Berg MP. Can nasal drug delivery bypass the blood-brain barrier? Questioning the direct transport theory. Drugs R. D. 8(3), 133-144 (2007). (Pubitemid 46707837)
25. US FDA. Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. (2005).
26. Reno F. Nonclinical toxicology. In: Principles and Practice of Pharmaceutical Medicine. Edwards LD, Fox AW, Stonier PD (Eds). Wiley-Blackwell, Oxford, UK, 68-78 (2011).
27. McMartin C, Hutchinson LE, Hyde R, Peters GE. Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity. J. Pharm. Sci. 76(7), 535-540 (1987).
28. Fisher AN, Brown K, Davis SS, Parr GD, Smith DA. The effect of molecular size on the nasal absorption of water-soluble compounds in the albino rat. J. Pharm. Pharmacol. 39(5), 357-362 (1987). (Pubitemid 17119492)
29. Sakane T, Akizuki M, Yamashita S, Nadai T, Hashida M, Sezaki H. The transport of a drug to the cerebrospinal fluid directly from the nasal cavity: the relation to the lipophilicity of the drug. Chem. Pharm. Bull. (Tokyo) 39(9), 2456-2458 (1991).
30. Sakane T, Akizuki M, Yamashita S, Sezaki H, Nadai T. Direct drug transport from the rat nasal cavity to the cerebrospinal fluid: the relation to the dissociation of the drug. J. Pharm. Pharmacol. 46(5), 378-379 (1994). (Pubitemid 24140941)
31. England RJ, Homer JJ, Knight LC, Ell SR. Nasal pH measurement: a reliable and repeatable parameter. Clin. Otolaryngol. Allied Sci. 24(1), 67-68 (1999). (Pubitemid 29116483)
32. Pujara CP, Shao Z, Duncan MR, Mitra AK. Effects of formulation variables on epithelial cell integrity: biochemical evaluations. Intl J. Pharm. (114), 7 (1995).
33. Ohwaki T, Ando H, Kakimoto F et al. Effects of dose, pH, and osmolarity on nasal absorption of secretin in rats. II: histological aspects of the nasal mucosa in relation to the absorption variation due to the effects of pH and osmolarity. J. Pharm. Sci. 76(9), 695-698 (1987). (Pubitemid 18026977)
34. Dufes C, Olivier JC, Gaillard F, Gaillard A, Couet W, Muller JM. Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats. Intl J. Pharm. 255(1-2), 87-97 (2003). (Pubitemid 36369593)
35. Olivier JC, Djilani M, Fahmy S, Couet W. In situ nasal absorption of midazolam in rats. Intl J. Pharm. 213(1-2), 187-192 (2001). (Pubitemid 32119474)
36. Greiff L, Andersson M, Wollmer P, Persson CG. Hypertonic saline increases secretory and exudative responsiveness of human nasal airway in vivo. Eur. Respir. J. 21(2), 308-312 (2003). (Pubitemid 36204547)
37. Dua R, Duncan M, Zia H, Needham TE. The influence of the enhancer dimyristoylphosphatidylglycerol and formulation factors on the nasal absorption of salmon calcitonin. Drug Deliv. 5(2), 127-134 (1998). (Pubitemid 28313922)
38. Furubayashi T, Inoue D, Kamaguchi A, Higashi Y, Sakane T. Influence of formulation viscosity on drug absorption following nasal application in rats. Drug Metab. Pharmacokinet. 22(3), 206-211 (2007).
39. Sarkar MA. Drug metabolism in the nasal mucosa. Pharm. Res. 9(1), 1-9 (1992).
40. Schipper NG, Verhoef JC, Merkus FW. The nasal mucociliary clearance: relevance to nasal drug delivery. Pharm. Res. 8(7), 807-814 (1991).
41. Harris AS, Nilsson IM, Wagner ZG, Alkner U. Intranasal administration of peptides: nasal deposition, biological response, and absorption of desmopressin. J. Pharm. Sci. 75(11), 1085-1088 (1986). (Pubitemid 17216555)
42. Davis SS, Illum L. Absorption enhancers for nasal drug delivery. Clin. Pharmacokinet. 42(13), 1107-1128 (2003). (Pubitemid 37357648)
43. Chen SC, Eiting K, Cui K et al. Therapeutic utility of a novel tight junction modulating peptide for enhancing intranasal drug delivery. J. Pharm. Sci. 95(6), 1364-1371 (2006). (Pubitemid 43874450)
44. Ozsoy Y, Gungor S, Cevher E. Nasal delivery of high molecular weight drugs. Molecules 14(9), 3754-3779 (2009).
45. Matsuyama T, Morita T, Horikiri Y, Yamahara H, Yoshino H. Enhancement of nasal absorption of large molecular weight compounds by combination of mucolytic agent and nonionic surfactant. J. Control. Release 110(2), 347-352 (2006). (Pubitemid 41827488)
46. Novakovic ZM, Leinung MC, Lee DW, Grasso P. Intranasal administration of mouse [D-Leu-4]OB3, a synthetic peptide amide with leptin-like activity, enhances total uptake and bioavailability in Swiss Webster mice when compared to intraperitoneal, subcutaneous, and intramuscular delivery systems. Regul. Pept. 154(1-3), 107-111 (2009).
47. Waldrop MA, Leinung MC, Lee DW, Grasso P. Intranasal delivery of mouse [D-Leu-4]- OB3, a synthetic peptide amide with leptin-like activity, improves energy balance, glycaemic control, insulin sensitivity and bone formation in leptin-resistant C57BLK/6-m db/db mice. Diabetes Obes. Metab. 12(10), 871-875 (2010).
48. Krauland AH, Alonso MJ. Chitosan/ cyclodextrin nanoparticles as macromolecular drug delivery system. Intl J. Pharm. 340(1-2), 134-142 (2007). (Pubitemid 47043346)
49. Varshosaz J, Sadrai H, Alinagari R. Nasal delivery of insulin using chitosan microspheres. J. Microencapsul. 21(7), 761-774 (2004). (Pubitemid 40100603)
50. Wang X, Zheng C, Wu Z et al. Chitosan- NAC nanoparticles as a vehicle for nasal absorption enhancement of insulin. J. Biomed. Mater. Res. B. Appl. Biomater. 88(1), 150-161 (2009).
51. Morimoto K, Yamaguchi H, Iwakura Y et al. Effects of proteolytic enzyme inhibitors on the nasal absorption of vasopressin and an analogue. Pharm. Res. 8(9), 1175-1179 (1991).
52. Gwak HS, Cho YM, Chun IK. Analgesic effects of intra-nasal enkephalins. J. Pharm. Pharmacol. 55(9), 1207-1212 (2003). (Pubitemid 37180006)
53. Agu RU, Vu Dang H, Jorissen M, Kinget R, Verbeke N. Metabolism and absorption enhancement of methionine enkephalin in human nasal epithelium. Peptides 25(4), 563-569 (2004). (Pubitemid 38681054)
54. Du Plessis LH, Lubbe J, Strauss T, Kotze AF. Enhancement of nasal and intestinal calcitonin delivery by the novel Pheroid fatty acid based delivery system, and by N-trimethyl chitosan chloride. Intl J. Pharm. 385(1-2), 181-186 (2010).
55. Kubek MJ, Domb AJ, Veronesi MC. Attenuation of kindled seizures by intranasal delivery of neuropeptide-loaded nanoparticles. Neurotherapeutics 6(2), 359-371 (2009).
56. Heurtault B, Frisch B, Pons F. Liposomes as delivery systems for nasal vaccination: strategies and outcomes. Expert. Opin. Drug Deliv. 7(7), 829-844 (2010).
57. Illum L, Jorgensen H, Bisgaard H, Krogsgaard O, Rossing N. Bioadhesive microspheres as a potential nasal drug delivery system. Intl J. Pharm. 39(3), 189-199 (1987). (Pubitemid 17147761)
58. Bjork E, Edman P. Degradable starch microspheres as a nasal delivery system for insulin. Intl J. Pharm. 47(1-3), 233-238 (1988).
59. Critchley H, Davis SS, Farraj NF, Illum L. Nasal absorption of desmopressin in rats and sheep. Effect of a bioadhesive microsphere delivery system. J. Pharm. Pharmacol. 46(8), 651-656 (1994). (Pubitemid 24249353)
60. Leitner VM, Guggi D, Krauland AH, Bernkop-Schnurch A. Nasal delivery of human growth hormone: in vitro and in vivo evaluation of a thiomer/glutathione microparticulate delivery system. J. Control. Release 100(1), 87-95 (2004). (Pubitemid 39445988)
61. Lim ST, Forbes B, Berry DJ, Martin GP, Brown MB. In vivo evaluation of novel hyaluronan/chitosan microparticulate delivery systems for the nasal delivery of gentamicin in rabbits. Intl J. Pharm. 231(1), 73-82 (2002). (Pubitemid 33086821)
62. Illum L, Fisher AN, Jabbal-Gill I, Davis SS. Bioadhesive starch microspheres and absorption enhancing agents act synergistically to enhance the nasal absorption of polypeptides. Intl J. Pharm. 222(1), 109-119 (2001). (Pubitemid 32525792)
63. Law SL, Huang KJ, Chou HY. Preparation of desmopressin-containing liposomes for intranasal delivery. J. Control. Release 70(3), 375-382 (2001). (Pubitemid 32155460)
64. Migliore MM, Vyas TK, Campbell RB, Amiji MM, Waszczak BL. Brain delivery of proteins by the intranasal route of administration: a comparison of cationic liposomes versus aqueous solution formulations. J. Pharm. Sci. 99(4), 1745-1761 (2010).
65. Marx D. Selecting a nasal spray pump. Inhalation Magazine, 4 (2009).
66. FDA. Guidance for Industry. Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products - chemistry, manufacturing, and controls documentation. (2002).
67. EMEA. Guideline on the Pharmaceutical Quality of Inhalation and Nasal Products. EMEA/CHM/QWP/49313/2005 (2006).
68. Huang SH, Gong TW, Gong SG. Isolation of epithelial cells in the developing primary lip and palate. J. Craniofac. Surg. 22(5), 1847-1851 (2011).
69. Yoo JW, Kim YS, Lee SH et al. Serially passaged human nasal epithelial cell monolayer for in vitro drug transport studies. Pharm. Res. 20(10), 1690-1696 (2003).
70. Liu Q, Shao X, Chen J et al. In vivo toxicity and immunogenicity of wheat germ agglutinin conjugated poly(ethylene glycol)-poly(lactic acid) nanoparticles for intranasal delivery to the brain. Toxicol. Appl. Pharmacol 251(1), 79-84 (2011).
71. Vetter A, Augustijns P, Bernkop-Schnurch A. Solubilizing agents in nasal formulations and their effect on ciliary beat frequency. Toxicol. In Vitro 26(1), 150-156 (2011).
72. Callens C, Adriaens E, Dierckens K, Remon JP. Toxicological evaluation of a bioadhesive nasal powder containing a starch and Carbopol 974 P on rabbit nasal mucosa and slug mucosa. J. Control. Release 76(1-2), 81-91 (2001). (Pubitemid 32786887)
73. Trimarchi M, Miluzio A, Nicolai P, Morassi ML, Bussi M, Marchisio PC. Massive apoptosis erodes nasal mucosa of cocaine abusers. J. Rhinol. 20(2), 160-164 (2006).
74. Sunderman FW, Jr. Nasal toxicity, carcinogenicity, and olfactory uptake of metals. Ann Clin. Lab. Sci. 31(1), 3-24 (2001).
75. Alexander TH, Davidson TM. Intranasal zinc and anosmia: the zinc-induced anosmia syndrome. Laryngoscope 116(2), 217-220 (2006). (Pubitemid 44383926)
76. Doty RL, Marcus A, Lee WW. Development of the 12-item cross-cultural smell identification test (CC-SIT). Laryngoscope 106(3 Pt 1), 353-356 (1996).
77. Gizurarson S. Animal models for intranasal drug delivery studies. A review article. Acta Pharm. Nord. 2(2), 105-122 (1990). (Pubitemid 20220363)
78. Menache MG, Hanna LM, Gross EA et al. Upper respiratory tract surface areas and volumes of laboratory animals and humans: considerations for dosimetry models. J. Toxicol. Environ. Health 50(5), 475-506 (1997).
79. Kao HD, Traboulsi A, Itoh S, Dittert L, Hussain A. Enhancement of the systemic and CNS specific delivery of L-dopa by the nasal administration of its water soluble prodrugs. Pharm. Res. 17(8), 978-984 (2000).
80. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm. Res. 10(7), 1093-1095 (1993). (Pubitemid 23211439)